recent articles
From HIT Consultant regarding PathAI: What You Should Know: PathAI, a pioneer in AI-powered pathology, announced a significant expansion of its PathExplore platform, adding six new oncology indications to its arsenal. The expansion...
PathAI and ConcertAI: Researchers derive novel insights through the combination of PathAI's proprietary tumor microenvironment features with ConcertAI's multi-modal clinical data BOSTON, April 25, 2023 /PRNewswire/ -- PathAI, a global...
PathAI: Latest research underscores advantages of digital tools at scale to enhance tumor microenvironment and biomarker understanding in non-small cell lung cancer and renal cell carcinoma BOSTON, Mass., April 11, 2023 /PRNewswire/...
PathAI PathExplore™ panel will empower oncology drug developers with improved tumor microenvironment spatial characterization from H&E, propelling a new phase of precision medicine. BOSTON, April 4, 2023 /PRNewswire/ -- PathAI, a...